Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
NEJM,
9.8 months with divarasib
Median progression-free survival
versus 5.7 months with sotorasib or adagrasibHR 0.58 (0.44–0.76)
17.7 months with divarasib
Median overall survival
versus 12.0 months with sotorasib or adagrasibHR 0.56 (0.41–0.78)
58.4% with divarasib
Objective response rate
versus 32.3% with sotorasib or adagrasib
- Patients
- 338
- Head-to-head
- Phase 3
- Primary endpoint, by BICR
- PFS
- Median follow-up
- 14.3 months
Take-home
A new phase 3 trial puts divarasib head-to-head against existing KRAS G12C inhibitors, with encouraging results.
In previously treated KRAS G12C-mutated advanced NSCLC, divarasib significantly improved median progression-free survival (9.8 vs 5.7 months; HR 0.58) and overall survival (17.7 vs 12.0 months; HR 0.56) compared with sotorasib or adagrasib.
Response rates were also higher (58.4% vs 32.3%), with fewer grade 3–4 treatment-related adverse events (24.6% vs 34.5%).
